New York, NY 2/20/13—Reuters reported that the potential buyout of Life Technologies is now less likely given the company’s current valuation. According to a person familiar with the matter, Thermo Fisher Scientific is doubtful about the purchase and is no longer pursuing it due to the rise in Life Technologies’ stock price to above $60 per share, following public disclosure of the company’s potential sale (see IBO 2/15/13). This price values the company at $11 billion. Offers by private equity firms valued the company at around that amount and would have to be increased to make the acquisition attractive to the Board, according to Reuters’ source. Reuters quoted one observer as stating that shareholders would require a price of 10.5 times EBITDA, but potential buyers would only be able to borrow up to seven times EBITDA to fund the purchase.